Patents Assigned to ImmunSys, Inc.
  • Patent number: 11696797
    Abstract: A method of non-thermally ablating undesirable tissue in the body by application of pulsed, bipolar, instant charge reversal electrical fields of sufficient energy to cause complete and immediate cell membrane rupture and destruction. Energy is delivered through radio frequency pulses of particular frequencies, wave characteristics, pulse widths and pulse numbers, such that enhanced physical stresses are placed on the cell membrane to cause its immediate and complete destruction thereby spilling the entire cell content and membrane constituents into, the extracellular space without denaturing proteins so as to enable an immunological response to destroy and remove the target tissue and similarly marked tissue elsewhere in the subject.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: July 11, 2023
    Assignee: ImmunSys, Inc.
    Inventor: Gary Onik
  • Patent number: 11612426
    Abstract: Provided herein are new compositions, methods, and devices to treat cancer through a combination of immunologic chemotherapeutic agents and ablation techniques. These compositions can include immune checkpoint inhibitors, cytokines and nucleic acid drugs that aid in eliciting an immune response to treat the tumor. The administration of these compositions in addition to various ablating techniques provides a presentation of the cancer cell antigens to the immune system and the immunologic targeting of the cancer.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: March 28, 2023
    Assignee: ImmunSys, Inc.
    Inventors: Gary Onik, James A. Miessau, DG Bostwick
  • Patent number: 11141216
    Abstract: An imaging, guidance, planning and treatment system integrated into a single unit or assembly of components, and a method for using same, that can be safely and effectively deployed to treat prostate cancer in all medical settings, including in a physician's office or in an outpatient setting. The system utilizes the novel process of Radio-Frequency Electrical Membrane Breakdown (“EMB” or “RFEMB”) to destroy the cellular membranes of unwanted or cancerous tissue without denaturing the intra-cellular contents of the cells comprising the tissue, thereby exposing tumor antigens and other intra-cellular components which can have an immunologic effect on local or distant cancerous tissue, with or without the addition of immunologic adjutant drugs. The system preferably comprises at least one EMB treatment probe 20, at least one trackable biopsy needle 200, at least one trackable anesthesia needle 300, and at least one controller unit for at least partially automating the treatment process.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: October 12, 2021
    Assignee: ImmunSys, Inc.
    Inventors: Gary M Onik, James A. Miessau, David G. Bostwick
  • Patent number: 10849678
    Abstract: A method of non-thermally ablating undesirable tissue in the body by application of pulsed, bipolar, instant charge reversal electrical fields of sufficient energy to cause complete and immediate cell membrane rupture and destruction. Energy is delivered through radio frequency pulses of particular frequencies, wave characteristics, pulse widths and pulse numbers, such that enhanced physical stresses are placed on the cell membrane to cause its immediate and complete destruction thereby spilling the entire cell content and membrane constituents into, the extracellular space without denaturing proteins so as to enable an immunological response to destroy and remove the target tissue and similarly marked tissue elsewhere in the subject.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: December 1, 2020
    Assignee: ImmunSys, Inc.
    Inventors: Gary M. Onik, James A. Miessau